233 related articles for article (PubMed ID: 25386824)
1. Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents.
Chohan TA; Qian H; Pan Y; Chen JZ
Curr Med Chem; 2015; 22(2):237-63. PubMed ID: 25386824
[TBL] [Abstract][Full Text] [Related]
2. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.
Tadesse S; Caldon EC; Tilley W; Wang S
J Med Chem; 2019 May; 62(9):4233-4251. PubMed ID: 30543440
[TBL] [Abstract][Full Text] [Related]
4. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
Sakurikar N; Thompson R; Montano R; Eastman A
Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
[TBL] [Abstract][Full Text] [Related]
5. Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure.
Jansa J; Jorda R; Škerlová J; Pachl P; Peřina M; Řezníčková E; Heger T; Gucký T; Řezáčová P; Lyčka A; Kryštof V
Eur J Med Chem; 2021 Apr; 216():113309. PubMed ID: 33711765
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review.
Volkart PA; Bitencourt-Ferreira G; Souto AA; de Azevedo WF
Curr Drug Targets; 2019; 20(7):716-726. PubMed ID: 30516105
[TBL] [Abstract][Full Text] [Related]
8. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
[TBL] [Abstract][Full Text] [Related]
9. A novel binding pocket of cyclin-dependent kinase 2.
Chen H; Van Duyne R; Zhang N; Kashanchi F; Zeng C
Proteins; 2009 Jan; 74(1):122-32. PubMed ID: 18615713
[TBL] [Abstract][Full Text] [Related]
10. Targeting CDK2 in cancer: challenges and opportunities for therapy.
Tadesse S; Anshabo AT; Portman N; Lim E; Tilley W; Caldon CE; Wang S
Drug Discov Today; 2020 Feb; 25(2):406-413. PubMed ID: 31839441
[TBL] [Abstract][Full Text] [Related]
11. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
[TBL] [Abstract][Full Text] [Related]
12. To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response.
Liu Q; Gao J; Zhao C; Guo Y; Wang S; Shen F; Xing X; Luo Y
DNA Repair (Amst); 2020 Jan; 85():102702. PubMed ID: 31731257
[TBL] [Abstract][Full Text] [Related]
13. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
[TBL] [Abstract][Full Text] [Related]
14. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Ibrahim DA; Ismail NS
Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
[TBL] [Abstract][Full Text] [Related]
16. Fusion of Structure and Ligand Based Methods for Identification of Novel CDK2 Inhibitors.
Mahajan P; Chashoo G; Gupta M; Kumar A; Singh PP; Nargotra A
J Chem Inf Model; 2017 Aug; 57(8):1957-1969. PubMed ID: 28723151
[TBL] [Abstract][Full Text] [Related]
17. Development of CDK2 and CDK5 Dual Degrader TMX-2172.
Teng M; Jiang J; He Z; Kwiatkowski NP; Donovan KA; Mills CE; Victor C; Hatcher JM; Fischer ES; Sorger PK; Zhang T; Gray NS
Angew Chem Int Ed Engl; 2020 Aug; 59(33):13865-13870. PubMed ID: 32415712
[TBL] [Abstract][Full Text] [Related]
18. Advances in Pyrazole Based Scaffold as Cyclin-dependent Kinase 2 Inhibitors for the Treatment of Cancer.
Shaikh J; Patel K; Khan T
Mini Rev Med Chem; 2022; 22(8):1197-1215. PubMed ID: 34711160
[TBL] [Abstract][Full Text] [Related]
19. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.
Li Y; Zhang J; Gao W; Zhang L; Pan Y; Zhang S; Wang Y
Int J Mol Sci; 2015 Apr; 16(5):9314-40. PubMed ID: 25918937
[TBL] [Abstract][Full Text] [Related]
20. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
